Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang LZ, Webber SE, Curtin NJ.

Mol Cancer Ther. 2007 Mar;6(3):945-56.

2.

PARP inhibitors for cancer therapy.

Curtin NJ.

Expert Rev Mol Med. 2005 Mar 15;7(4):1-20. Review.

PMID:
15836799
3.

Chemopotentiation by PARP inhibitors in cancer therapy.

Tentori L, Graziani G.

Pharmacol Res. 2005 Jul;52(1):25-33. Review.

PMID:
15911331
4.

PARP inhibitor development for systemic cancer targeting.

Zaremba T, Curtin NJ.

Anticancer Agents Med Chem. 2007 Sep;7(5):515-23. Review.

PMID:
17896912
5.

The potential role and application of PARP inhibitors in cancer treatment.

Chalmers AJ.

Br Med Bull. 2009;89:23-40. doi: 10.1093/bmb/ldp005. Epub 2009 Feb 9. Review.

PMID:
19208614
6.

Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.

Chalmers AJ, Lakshman M, Chan N, Bristow RG.

Semin Radiat Oncol. 2010 Oct;20(4):274-81. doi: 10.1016/j.semradonc.2010.06.001. Review.

PMID:
20832020
7.

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

Ashworth A.

J Clin Oncol. 2008 Aug 1;26(22):3785-90. doi: 10.1200/JCO.2008.16.0812. Epub 2008 Jun 30. Review.

PMID:
18591545
8.

PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.

Drew Y, Plummer R.

Drug Resist Updat. 2009 Dec;12(6):153-6. doi: 10.1016/j.drup.2009.10.001. Epub 2009 Nov 25. Review.

PMID:
19939726
9.

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.

Ratnam K, Low JA.

Clin Cancer Res. 2007 Mar 1;13(5):1383-8. Review.

10.

DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.

Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ.

Curr Med Chem. 2012;19(23):3874-85. Review.

PMID:
22788763
11.

The antimitotic potential of PARP inhibitors, an unexplored therapeutic alternative.

Iglesias P, Costoya JA.

Curr Top Med Chem. 2014;14(20):2346-65. Review.

PMID:
25434352
12.

Targeted therapy for brain tumours: role of PARP inhibitors.

Leonetti C, Biroccio A, Graziani G, Tentori L.

Curr Cancer Drug Targets. 2012 Mar;12(3):218-36. Review.

PMID:
22268386
13.

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.

Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A, Miao ZH.

J Med Chem. 2016 Nov 10;59(21):9575-9598. Epub 2016 Jul 27. Review.

PMID:
27416328
14.

PARP inhibition: PARP1 and beyond.

Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG.

Nat Rev Cancer. 2010 Apr;10(4):293-301. doi: 10.1038/nrc2812. Epub 2010 Mar 4. Review.

15.

PARP inhibitors: polypharmacology versus selective inhibition.

Ekblad T, Camaioni E, Schüler H, Macchiarulo A.

FEBS J. 2013 Aug;280(15):3563-75. doi: 10.1111/febs.12298. Epub 2013 May 24. Review.

16.

The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer.

Madhusudan S, Middleton MR.

Cancer Treat Rev. 2005 Dec;31(8):603-17. Epub 2005 Nov 17. Review.

PMID:
16298073
17.

PARP inhibitors as antitumor agents: a patent update (2013-2015).

Yuan Z, Chen J, Li W, Li D, Chen C, Gao C, Jiang Y.

Expert Opin Ther Pat. 2017 Mar;27(3):363-382. doi: 10.1080/13543776.2017.1259413. Epub 2016 Nov 21. Review.

PMID:
27841036

Supplemental Content

Support Center